Edges in Network
| Network | GSE5851_top8000 - GSE5851 - SiGN-BN NNSR |
| Network Description | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| Node | LGALS3 |
| Upstream (Parents) |
|---|
| (<<) S100A10 → LGALS3 |
| (<<) CEACAM5 → LGALS3 |
| (<<) HEPH → LGALS3 |
| (<<) S100A6 → LGALS3 |
| Downstream (Children) |
|---|
| LGALS3 → ABR (>>) |
| LGALS3 → ACTN4 (>>) |
| LGALS3 → ATP1B3 (>>) |
| LGALS3 → FXYD5 (>>) |
| LGALS3 → PLCE1 (>>) |
| LGALS3 → KCTD13 (>>) |
| LGALS3 → PRKCD (>>) |
| LGALS3 → PARM1 (>>) |
| LGALS3 → S100A10 (>>) |
| LGALS3 → CCRL2 (>>) |
| LGALS3 → SSH3 (>>) |
| LGALS3 → CD97 (>>) |
| LGALS3 → CEACAM5 (>>) |
| LGALS3 → GPA33 (>>) |
| LGALS3 → CA12 (>>) |
| LGALS3 → NBL1 (>>) |
| LGALS3 → KCNN4 (>>) |
| LGALS3 → VILL (>>) |
| LGALS3 → ATP2A3 (>>) |
| LGALS3 → HEPH (>>) |
| LGALS3 → S100A6 (>>) |
| LGALS3 → HHLA2 (>>) |
| LGALS3 → ERN2 (>>) |
| LGALS3 → VDR (>>) |
| LGALS3 → S100A11 (>>) |
| LGALS3 → CAPG (>>) |
| LGALS3 → FHL2 (>>) |
| LGALS3 → CD9 (>>) |
